6th June, 2019

To,
National Stock Exchange of India Limited
Exchange Plaza
C-1, Block 'G'Bandra Kurla Complex,
Bandra (E), Mumbai – 400051.
Scrip Code: MARKSANS

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Fort,
Mumbai – 400 001.
Scrip Code: 524404

Sub: Receipt of Establishment Inspection Report (EIR) from the US FDA

Dear Sirs,

We are pleased to announce receipt of Establishment Inspection Report (EIR) from the US FDA in respect of inspection of the Company's Goa facility carried out from 25th February to 6th March 2019.

This is for your information and records.

Thanking you.

Yours faithfully,

For Marksans Pharma Limited

Harshavardhan Panigrahi

Company Secretary & Manager - Legal

About Marksans Pharma Limited

Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The Company's manufacturing facilities are approved by several leading regulatory agencies including UK MHRA, US FDA & Australia TGA. The Company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterologicals and Anti-allergies. The Company is marketing these products globally.